Brian Rini, MD

Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses subgroup findings from the IMmotion151 trial in metastatic renal cell carcinoma (mRCC).

IMmotion151 evaluated the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) compared with sunitinib (Sutent) in patients with mRCC. In an effort to differentiate response by subgroup, Rini says that findings varied according to molecular profile and risk factor.

In the T effectorhigh subgroup, patients did better with the combination of atezolizumab plus bevacizumab. Rini says that is not surprising, as these patients are known to respond well to immunotherapy. Patients who had gene expression that was angiogenesis-high did better on sunitinib than those with tumors that were angiogenesis-low.

Videos

Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses subgroup findings from the IMmotion151 trial in metastatic renal cell carcinoma.&nbsp;

Molecular Subgroup Findings of IMmotion151 in RCC

Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses the basis for the ongoing phase III KEYNOTE-426 trial, which is exploring pembrolizumab (Keytruda) plus axitinib (Inlyta) versus sunitinib (Sutent) alone in treatment-naive advanced metastatic renal cell carcinoma.

Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses the basis for the ongoing phase III KEYNOTE-426 trial, which is exploring pembrolizumab (Keytruda)&nbsp;plus axitinib (Inlyta) versus sunitinib (Sutent) alone in treatment-naive advanced metastatic renal cell carcinoma.

Overview of a Phase III Trial of Pembrolizumab Plus Axitinib in RCC

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).

About 20 years ago, subsequent cytoreductive nephrectomy and interferon demonstrated a survival advantage in patients with metastatic RCC

Researchers and oncologists question whether cytoreductive nephrectomy should remain a part of the treatment approach in this space

Several retrospective analyses have supported the current role of cytoreductive nephrectomy

Patient selection bias prevents too much weight being placed on these retrospective studies

Two prospective studies are underway, though it will be some time before those read out

Brian Rini, MD | Authors

Articles

Molecular Subgroup Findings of IMmotion151 in RCC

Overview of a Phase III Trial of Pembrolizumab Plus Axitinib in RCC

The Role of Cytoreductive Nephrectomy in Patients With Synchronous Metastases From RCC